Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

901. The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer

, Physics 1999;45(5):1103-4. Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Cancer Care Facilities /economics; Case-Control Studies; Cost-Benefit Analysis; Follow-Up Studies; Health Care Costs; Hospital Charges /statistics & Humans; Male; Medicare; Middle Aged; Philadelphia; Prostate-Specific Antigen /blood; Prostatic Neoplasms /economics /pathology /radiotherapy; Radiotherapy, Conformal /economics; Retrospective Studies; Survival Rate; Treatment Outcome; United States (...) The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer Horwitz E M, Hanlon A L, Pinover W H, Hanks G E

1999 NHS Economic Evaluation Database.

902. Brachytherapy for prostate cancer

Brachytherapy for prostate cancer Brachytherapy for prostate cancer Brachytherapy for prostate cancer Wills F, Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wills F, Hailey D. Brachytherapy for prostate cancer. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). AHFMR HTA Report 17. 1999 Authors' objectives (...) This report aims to review the recent literature relating to the use of brachytherapy in the treatment of prostate cancer. Authors' conclusions Biochemical outcomes indicate that brachytherapy is a reasonable option for treatment of early prostate cancer in the short term, or as a boost to external beam radiation in more advanced stages. However, its potential for influencing overall outcomes, particularly long term morbidity and survival are unknown. Alternative or complementary treatments

1999 Health Technology Assessment (HTA) Database.

903. Predictive genetic testing for breast and prostate cancer

cancer are the second leading causes of death and the most frequently diagnosed malignancies in Canadian women and men, respectively. Age, ethnicity, and family history are definite risk factors for breast and prostate cancer. Hereditary breast and prostate cancers have been associated with alterations in the expression of tumour suppressor genes and oncogenes. The majority of hereditary breast cancers can be attributed to germ-line mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 (...) mutations in BRCA1 and one founder mutation in BRCA2, appear in about one-third of the breast cancer patients of Ashkenazi Jewish descent. Protein expression of the oncogene Bcl-2 (B cell leukemia/lymphoma-2) and p53 have roles as independent prognostic markers for disease-free survival after radical treatment for prostate cancer. Predisposing mutations in the hereditary prostate cancer 1 gene (HPC1) are responsible for only a minority of familial prostate cancer cases and they are likely to be most

1999 Health Technology Assessment (HTA) Database.

904. Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer

in detecting metastatic prostate cancer. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). HTB-5. 1999 Authors' objectives To summarise the effectiveness and cost-effectiveness of In-111 Capromab Pendetide in detecting metastatic prostate cancer. Authors' conclusions Imaging with In-111 Capromab Pendetide provides an additional method for detection of metastatic disease in prostate cancer. As the images are difficult to interpret, it would be essential for clinicians to receive (...) Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer Howell T, Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Howell T, Hailey D. Use of In-111 Capromab Pendetide

1999 Health Technology Assessment (HTA) Database.

905. Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project)

Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Schersten T, Baile M A, Asua J, Jonsson E Citation Schersten T, Baile M A, Asua J, Jonsson E. Deteccion precoz del cancer de prostata (projecto (...) INAHTA). Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Vitoria Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-99-03. 1999 Authors' objectives

To summarize scientific evidence regarding the effectiveness and cost-effectiveness of mass screening for prostate cancer.

Authors' conclusions Mass screening for prostate cancer is not recommended because of lack of evidence regarding the benefits and the considerable risks of adverse effects

1999 Health Technology Assessment (HTA) Database.

906. The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer

, as a result of the treatment, their count falls below defined critical thresholds. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients receiving radiation therapy for prostate cancer. Patients with distant metastatic disease, undergoing prior radiotherapy or chemotherapy, with adoption of palliative strategies, or lack of CBC following baseline were excluded. Setting The setting was secondary care. The economic study (...) The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer Blank K R, Cascardi M A, Kao G D Record Status This is a critical abstract of an economic evaluation that meets the criteria

1999 NHS Economic Evaluation Database.

907. Screening for prostate cancer, Norwegian review of international studies

the quality of life. Due to the insufficiencies in the current level of knowledge on prostate cancer, we lack the fundamental scientific knowledge on which to base decisions regarding those medical inventions best suited to prevent, diagnose or treat this disease. Efforts should be taken to increase our understanding of the disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Mass Screening; Prostatic Neoplasms Language Published Norwegian Country of organisation Norway English (...) Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Norwegian Knowledge Centre for the Health Services Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Norwegian Knowledge

1999 Health Technology Assessment (HTA) Database.

908. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. Full Text available with Trip Pro

. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy.We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status.Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group (...) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate

1998 NEJM Controlled trial quality: uncertain

909. The association between vasectomy and prostate cancer: a systematic review of the literature

Inc.; 1992. This additional published commentary may also be of interest. Millard PS. Review: bias may contribute to the association between vasectomy and prostate cancer. Evid Based Med 1999;4:92. Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Case-Control Studies; Cohort Studies; Humans; Male; Middle Aged; Prostatic Neoplasms /etiology; Risk Factors; Vasectomy /adverse effects AccessionNumber 11998001380 Date bibliographic record published 31/12/1999 Date abstract record (...) The association between vasectomy and prostate cancer: a systematic review of the literature The association between vasectomy and prostate cancer: a systematic review of the literature The association between vasectomy and prostate cancer: a systematic review of the literature Bernal-Delgado E, Latour-Perez J, Pradas-Arnal F, Gomez-Lopez L I Authors' objectives To evaluate the possible association between vasectomy and prostate cancer. Searching MEDLINE, EMBASE and IME (Spanish Index Medicus

1998 DARE.

910. Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials

with caution. Implications of the review for practice and research The authors state that longer follow-up research is needed to validate these measures as good surrogates for tumour specific survival. Bibliographic details Bonney W W, Schned A R, Timberlake D S. Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials. Journal of Urology 1998; 160(5): 1754-1760 PubMedID Indexing Status Subject indexing assigned by NLM MeSH (...) Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials Bonney W W, Schned A R, Timberlake D S Authors' objectives To assess

1998 DARE.

911. Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate-specific antigen levels and biochemical control: a comprehensive review of the literature

: a comprehensive review of the literature Vicini F A, Horwitz E M, Kini V R, Stromberg J S, Martinez A A Authors' objectives To review all the available literature on prostate cancer treatment employing radiotherapy (RT), to determine if any conclusions can be reached regarding the optimal radiotherapeutic management of this disease when serum prostate-specific antigen (PSA) levels are used to both stratify patients and monitor disease outcome. Searching MEDLINE was searched from 1986 to 1997 for publications (...) definitions. The authors' conclusions are valid. Implications of the review for practice and research Due to the marked variation in definitions of disease staging and cure, future research is required to assess RT for localised prostate cancer using standardised definitions. Bibliographic details Vicini F A, Horwitz E M, Kini V R, Stromberg J S, Martinez A A. Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate-specific antigen levels and biochemical control

1998 DARE.

912. Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden

was used to describe the screening, diagnosis and therapy processes as costs for the screening examinations and costs for each newly diagnosed case of cancer in the form of type of cancer and therapy. Costs were calculated for the course of the disease, and all treatment measures were included. The cost for examination of suspected cases of cancer was calculated to be an average of two methods (fine-needle biopsy and transurethral resection) with microscopic examination of tissue from the prostate (...) , the natural history of the disease, and treatments, as well as on screening programmes. To this end, small-scale trials and modelling are recommended. Source of funding Financial support from the National Pharmacy Corporation's fund for research and studies in health economics and social pharmacy and the County Council of Ostergotland, Sweden. Bibliographic details Holmberg H, Carlsson P, Lofman O, Varenhorst E. Economic evaluation of screening for prostate cancer: a randomized population based programme

1998 NHS Economic Evaluation Database.

913. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer Aronson N, Seidenfeld J, Samson DJ, Albertson PC, Bayoumi AM, Bennett C Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Aronson N, Seidenfeld J, Samson DJ, Albertson PC, Bayoumi AM, Bennett C. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 4. 1998 Authors' objectives This report

1998 Health Technology Assessment (HTA) Database.

914. Cryosurgery for prostate cancer

Cryosurgery for prostate cancer Cryosurgery for prostate cancer Cryosurgery for prostate cancer Alberta Heritage Foundation for Medical Research Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alberta Heritage Foundation for Medical Research. Cryosurgery for prostate cancer. Edmonton: Alberta Heritage Foundation for Medical Research (...) (AHFMR). Technote TN 16. 1998 Authors' objectives This report has been prepared in response to a request for an update on the status of cryosurgery as a treatment for prostatic cancer, in relation to reimbursement issues. There was interest in whether the procedure is still considered experimental or in the research stage. Authors' conclusions Cryosurgery for prostate cancer is a technology whose efficacy has yet to be established. The only long-term results available were obtained from studies which

1998 Health Technology Assessment (HTA) Database.

915. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based (...) mitoxantrone and prednisone (M+P) was compared to prednisone alone (P) in patients with symptomatic hormone-resistant prostate cancer (HRPC). Type of intervention Palliative care. Economic study type Cost-utility analysis. Study population The study population comprised patients with symptomatic HRPC and pain. No further inclusion or exclusion criteria were reported. Setting The setting was tertiary care. The economic study was carried out in Canada. Dates to which data relate The dates during which

1998 NHS Economic Evaluation Database.

916. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. Full Text available with Trip Pro

). The proportion of surviving patients who were free of disease at five years was 85 percent (95 percent confidence interval, 78 to 92 percent) in the combined-treatment group and 48 percent (95 percent confidence interval, 38 to 58 percent) in the radiotherapy group (P<0.001).Adjuvant treatment with goserelin, when started simultaneously with external irradiation, improves local control and survival in patients with locally advanced prostate cancer. (...) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. We conducted a randomized, prospective trial comparing external irradiation with external irradiation plus goserelin (an agonist analogue of gonadotropin-releasing hormone that reduces testosterone secretion) in patients with locally advanced prostate cancer.From 1987 to 1995, 415 patients with locally advanced prostate cancer were randomly assigned to receive radiotherapy alone

1997 NEJM Controlled trial quality: uncertain

917. Diagnosis, management and screening of early localised prostate cancer

in the follow-up of men with known prostate cancer, to monitor tumour progression. The 'gold' standard for staging localised disease is surgery, including lymphadenectomy. Clinical staging with DRE, PSA and TRUS is unreliable. There is only a 10% difference in survival rate between radical and conservative treatment. Conservative management is, therefore, a reasonable option for men with localised disease. In the absence of evidence from RCTs concerning the relative benefits of treatments, informed patient (...) Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Selley S, Donovan J, Faulkner A, Coast J, Gillatt D Authors' objectives To assess the clinical and cost-effectiveness of methods for the diagnosis, treatment and screening of early localised prostate cancer. Searching EMBASE, Cancerlit, MEDLINE, the Social Sciences Citation Index

1997 DARE.

918. Use of strontium-89 in patients with endocrine-refractory carcinoma of the prostate metastatic to bone

Use of strontium-89 in patients with endocrine-refractory carcinoma of the prostate metastatic to bone Use of strontium-89 in patients with endocrine-refractory carcinoma of the prostate metastatic to bone Use of strontium-89 in patients with endocrine-refractory carcinoma of the prostate metastatic to bone Brundage M D, Crook J M, Lukka H, Genitourinary Cancer Disease Site Group CRD summary This review found the benefits of strontium-89 versus placebo in men with hormone-refractory prostate (...) for further radiotherapy, could also be investigated. The authors suggested that data are needed on validated palliative outcome measures in larger studies before a cost-effectiveness analysis is feasible. Funding Cancer Care Ontario; Ontario Ministry of Health and Long-term Care. Bibliographic details Brundage M D, Crook J M, Lukka H, Genitourinary Cancer Disease Site Group. Use of strontium-89 in patients with endocrine-refractory carcinoma of the prostate metastatic to bone. Cancer Care Ontario

1997 DARE.

919. Erectile functioning of men treated for prostate carcinoma

will be produced. Bibliographic details Robinson J W, Dufour M S, Fung T S. Erectile functioning of men treated for prostate carcinoma. Cancer 1997; 79(3): 538-544 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Databases, Factual; Erectile Dysfunction /etiology /physiopathology; Humans; Male; Penile Erection /radiation effects; Prostatectomy /adverse effects; Prostatic Neoplasms /physiopathology /radiotherapy /surgery /therapy AccessionNumber 11997000244 Date bibliographic record published 30 (...) Erectile functioning of men treated for prostate carcinoma Erectile functioning of men treated for prostate carcinoma Erectile functioning of men treated for prostate carcinoma Robinson J W, Dufour M S, Fung T S Authors' objectives To assess the rates of erectile dysfunction associated with external beam radiotherapy and radical prostatectomy in men treated for prostate carcinoma. Searching The Alberta Health Knowledge Network, which includes MEDLINE and Cancerlit was searched in 1994

1997 DARE.

920. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

1997 DARE.